Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced recruitment of the first patient into its EVOLUTION Phase 2 clinical trial following successful achievement of key safety and proof of concept milestones in Phase 1.
Immunic to Participate in Investor and Scientific Conferences in February – Biotech Investments
Issuer: Immunic AG / Key word(s): Conference 04.02.2025 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate